Skip to main content
SpringerLink
Log in

Focal Therapy and Active Surveillance of Prostate Cancer in East and Southeast Asia

  • Chapter
  • First Online:
Imaging and Focal Therapy of Early Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

Abstract

The majority of prostate-specific antigen (PSA) screen-detected prostate cancers are low grade and low stage, rendering them suitable for active surveillance in the low-risk group and for focal therapy of the intermediate-risk group with low-volume cancers. While the importance of prostate cancer varies between more developed and less developed countries in East and Southeast Asia due to competing causes of mortality and differential penetrance of PSA screening, there has been a general increase in the incidence of prostate cancer. Cultural differences in decision-making and the acceptance of gland-preserving strategies as well as geographic variability in the dissemination of advanced imaging, biopsy, and ablative technologies are also significant factors in the uptake of focal therapy and active surveillance in East and Southeast Asia. The currently published literature on active surveillance and focal therapy in Asia remains sparse. With an aging population and longer life expectancy due to improving healthcare, focal therapy and active surveillance will become increasingly important in the management of prostate cancer in Asia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chowdhury S, Robinson D, Cahill D, Rodriguez-Vida A, Holmberg L, Moller H. Causes of death in men with prostate cancer: an analysis of 50,000 men from the thames cancer registry. BJU Int. 2013;112(2):182–9.

    Article  PubMed  Google Scholar 

  2. National Geographic S. National geographic atlas of the world. National Geographic Society. Washington, DC: National Geographic Society; 1999.

    Google Scholar 

  3. Reid TR. Confucius lives next door: what living in the east teaches us about living in the west. New York: Random House; 1999.

    Google Scholar 

  4. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Globocan 2012 v1.0, cancer incidence and mortality worldwide: Iarc cancerbase no. 11 [internet]. Lyon: International Agency for Research on Cancer; 2013 [3/2/2016]; Available from: http://globocan.iarc.fr.

    Google Scholar 

  5. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, et al. Latent carcinoma of prostate at autopsy in seven areas. The international agency for research on cancer, Lyons, France. Int J Cancer. 1977;20(5):680–8.

    Article  CAS  PubMed  Google Scholar 

  6. Cullen J, Elsamanoudi S, Brassell SA, Chen Y, Colombo M, Srivastava A, et al. The burden of prostate cancer in Asian nations. J Carcinog. 2012;11:7.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Sim HG, Cheng CW. Changing demography of prostate cancer in asia. Eur J Cancer. 2005;41(6):834–45.

    Article  PubMed  Google Scholar 

  8. Grulich AE, McCredie M, Coates M. Cancer incidence in asian migrants to new south wales, Australia. Br J Cancer. 1995;71(2):400–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, et al. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol. 2008;37(1):147–60.

    Article  PubMed  Google Scholar 

  10. Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F, et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer. 2008;123(2):421–9.

    Article  CAS  PubMed  Google Scholar 

  11. Myrtle J, Ivor L. Measurement of prostate-specific antigen (psa) in the serum by a two-site immunometric method (hybritech tandem-r/tandem-e psa). In: Catalona W, Coffey D, Karr J, editors. Clinical aspects of prostate cancer: assessment of new diagnostic and management procedures. New York: Elsevier; 1989. p. 161–71.

    Google Scholar 

  12. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7):860–4.

    Article  CAS  PubMed  Google Scholar 

  13. Hong GE, Kong CH, Singam P, Cheok LB, Zainuddin ZM, Azrif M. Seven-year review of prostate carcinomas diagnosed by trus biopsy in a single malaysian institution. Asian Pac J Cancer Prev. 2010;11(5):1351–3.

    PubMed  Google Scholar 

  14. Lim J, Bhoo-Pathy N, Sothilingam S, Malek R, Sundram M, Hisham Bahadzor B, et al. Ethnicity is an independent determinant of age-specific psa level: findings from a multiethnic asian setting. PLoS One. 2014;9(8):e104917.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Chia SE, Lau WK, Cheng C, Chin CM, Tan J, Ho SH. Prostate-specific antigen levels among Chinese, Malays and Indians in Singapore from a community-based study. Asian Pac J Cancer Prev. 2007;8(3):375–8.

    PubMed  Google Scholar 

  16. Teo JK, Poh BK, Ng FC, Fong YK. Detection rate of prostate cancer on the basis of the vienna nomogram: a Singapore study. Korean J Urol. 2014;55(4):245–8.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Yang WJ, Lee DH, Chung BH, Cho JS, Choi YD, Kim SJ, et al. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study. Urology. 2006;67(2):333–6.

    Article  PubMed  Google Scholar 

  18. Ng LG, Yip S, Tan PH, Yuen J, Lau W, Cheng C. Improved detection rate of prostate cancer using the 10-core biopsy strategy in Singapore. Asian J Surg. 2002;25(3):238–43.

    Article  CAS  PubMed  Google Scholar 

  19. Egawa S, Matsumoto K, Yoshida K, Iwamura M, Kuwao S, Koshiba K. Results of transrectal ultrasound-guided biopsies and clinical significance of Japanese prostate cancer. Jpn J Clin Oncol. 1998;28(11):666–72.

    Article  CAS  PubMed  Google Scholar 

  20. Sothilingam S, Sundram M, Malek R, Sahabuddin RM. Prostate cancer screening perspective, Malaysia. Urol Oncol. 2010;28(6):670–2.

    Article  PubMed  Google Scholar 

  21. Teoh JY, Yuen SK, Tsu JH, Wong CK, Ho B, Ng AT, et al. Prostate cancer detection upon transrectal ultrasound-guided biopsy in relation to digital rectal examination and prostate-specific antigen level: what to expect in the Chinese population? Asian J Androl. 2015;17(5):821–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Kuo YJ, Lin SF, Chang YH, Pan CC. Trends in prostate needle biopsy diagnosis. A ten year experience of a medical center in Taiwan. Pathol Int. 2012;62(3):191–8.

    Article  PubMed  Google Scholar 

  23. Fu Q, Moul JW, Banez LL, Sun L, Mouraviev V, Xie D, et al. Association between percentage of tumor involvement and gleason score upgrading in low-risk prostate cancer. Med Oncol. 2012;29(5):3339–44.

    Article  PubMed  Google Scholar 

  24. Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, et al. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with gleason 6 prostate cancer by contemporary multicore prostate biopsy. BJU Int. 2012;110(11 Pt B):E494–9.

    Article  PubMed  Google Scholar 

  25. Imamoto T, Utsumi T, Takano M, Komaru A, Fukasawa S, Suyama T, et al. Development and external validation of a nomogram predicting the probability of significant gleason sum upgrading among Japanese patients with localized prostate cancer. Prostate Cancer. 2011;2011:754382. doi:10.1155/2011/754382.

    PubMed  Google Scholar 

  26. Tan G, Ho H, Huang H, Cheng CWS, Lau WKO. Pathological outcome in men with prostate cancer suitable for active surveillance after radical prostatectomy. Proc Singapore Healthcare. 2012;21(2):102–8.

    Article  Google Scholar 

  27. Tay KJ, Mendez M, Moul JW, Polascik TJ. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? Curr Opin Urol. 2015;25(3):185–90.

    Article  PubMed  Google Scholar 

  28. Arumainayagam N, Ahmed HU, Moore CM, Freeman A, Allen C, Sohaib SA, et al. Multiparametric Mr imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology. 2013;268(3):761–9.

    Article  PubMed  Google Scholar 

  29. Rosenkrantz AB, Mendrinos S, Babb JS, Taneja SS. Prostate cancer foci detected on multiparametric magnetic resonance imaging are histologically distinct from those not detected. J Urol. 2012;187(6):2032–8.

    Article  PubMed  Google Scholar 

  30. Kitamura K, Muto S, Yokota I, Hoshimoto K, Kaminaga T, Noguchi T, et al. Feasibility of multiparametric prostate magnetic resonance imaging in the detection of cancer distribution: histopathological correlation with prostatectomy specimens. Prostate Int. 2014;2(4):188–95.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Matsuoka Y, Numao N, Saito K, Tanaka H, Kumagai J, Yoshida S, et al. Combination of diffusion-weighted magnetic resonance imaging and extended prostate biopsy predicts lobes without significant cancer: application in patient selection for hemiablative focal therapy. Eur Urol. 2014;65(1):186–92.

    Article  PubMed  Google Scholar 

  32. Matsuoka Y, Numao N, Saito K, Tanaka H, Kumagai J, Yoshida S, et al. Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsy. BJU Int. 2016;117(1):94–101.

    Article  PubMed  Google Scholar 

  33. Kan RW, Kan CF, Ho LY, Chan SW. Pre-operative tumor localization and evaluation of extra-capsular extension of prostate cancer: how misleading can it be? Urol J. 2014;11(3):1615–9.

    PubMed  Google Scholar 

  34. Jeong CW, Ku JH, Moon KC, Hong SK, Byun SS, Cho JY, et al. Can conventional magnetic resonance imaging, prostate needle biopsy, or their combination predict the laterality of clinically localized prostate cancer? Urology. 2012;79(6):1322–7.

    Article  PubMed  Google Scholar 

  35. Shoji S, Hiraiwa S, Endo J, Hashida K, Tomonaga T, Nakano M, et al. Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience. Int J Urol. 2015;22(2):173–8.

    Article  PubMed  Google Scholar 

  36. Ho H, Yuen JS, Mohan P, Lim EW, Cheng CW. Robotic transperineal prostate biopsy: Pilot clinical study. Urology. 2011;78(5):1203–8.

    Article  CAS  PubMed  Google Scholar 

  37. Tay KJ, Ho H, Huang H, Law Z, Koh Z, Yuen J, et al. Robotic transperineal saturation biopsy approximates the “truth” in defining low-risk prostate cancer. Urology. 2013;82(3):S70.

    Google Scholar 

  38. Tay KJ, Chen K, Law YM, Ho H, Yuen J, Cheng C. Early outcomes of combination mri-targeted and saturation trans-perineal biopsy in restaging low-risk prostate cancer for active surveillance (mp48-08). J Urol. 2015;193(4):e597.

    Article  Google Scholar 

  39. Lee YK, Lee PY, Cheong AT, Ng CJ, Abdullah KL, Ong TA, et al. To share or not to share: Malaysian healthcare professionals' views on localized prostate cancer treatment decision making roles. PLoS One. 2015;10(11):e0142812.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Tay KJ, Mohamad Zam NA, Cheng CW. Prevailing attitudes towards cancer: a multicultural survey in a tertiary outpatient setting. Ann Acad Med Singapore. 2013;42(10):492–8.

    PubMed  Google Scholar 

  41. Ruhnke GW, Wilson SR, Akamatsu T, Kinoue T, Takashima Y, Goldstein MK, et al. Ethical decision making and patient autonomy: a comparison of physicians and patients in Japan and The United States. Chest. 2000;118(4):1172–82.

    Article  CAS  PubMed  Google Scholar 

  42. Dai Q. Informed consent in china: Status quo and its future. Med Law Int. 2003;6(1):53–71.

    Article  PubMed  Google Scholar 

  43. Venderbos LD, van den Bergh RC, Roobol MJ, Schroder FH, Essink-Bot ML, Bangma CH, et al. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psychooncology. 2015;24(3):348–54.

    Google Scholar 

  44. van den Bergh RC, Essink-Bot ML, Roobol MJ, Wolters T, Schroder FH, Bangma CH, et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009;115(17):3868–78.

    Article  PubMed  Google Scholar 

  45. Isa MR, Moy FM, Abdul Razack AH, Md Zainuddin Z, Zainal NZ. Anxiety status and its relationship with general health related quality of life among prostate cancer patients in two university hospitals in Kuala Lumpur, Malaysia. Iran J Public Health. 2013;42(3):240–8.

    PubMed  PubMed Central  Google Scholar 

  46. Lin YH. Treatment decision regret and related factors following radical prostatectomy. Cancer Nurs. 2011;34(5):417–22.

    Article  PubMed  Google Scholar 

  47. Lin YH, Yu TJ, Lin VC, Yang MS, Kao CC. Changes in quality of life among prostate cancer patients after surgery. Cancer Nurs. 2012;35(6):476–82.

    Article  PubMed  Google Scholar 

  48. Sugimoto M, Hirama H, Yamaguchi A, Koga H, Hashine K, Ninomiya I, et al. Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of Prias-Japan. World J Urol. 2015;33(7):981–7.

    Article  PubMed  Google Scholar 

  49. Mitsuzuka K, Koga H, Sugimoto M, Arai Y, Ohyama C, Kakehi Y, et al. Current use of active surveillance for localized prostate cancer: a nationwide survey in Japan. Int J Urol. 2015;22(8):754–9.

    Article  PubMed  Google Scholar 

  50. Ha JY, Kim BH, Park CH, Kim CI. Early experience with active surveillance in low-risk prostate cancer treated. Korean J Urol. 2014;55(3):167–71.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Tay KJ, Huang HH, Lee LS, Cheng CWS, Yuen JSP. A treatment journey of 108 men on active surveillance for prostate cancer: why men change? BJU international. Hoboken: Wiley-Blackwell; 2014.

    Google Scholar 

  52. Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol. 2008;38(3):192–9.

    Article  PubMed  Google Scholar 

  53. Tay KJ, Cheng CW, Kwek JW, Thng CH, Lau WK, Ho HS, et al. Initial experience with MRGFUS focal therapy for low-risk prostate cancer. J Endourol. 2011;25(1):A99–100.

    Google Scholar 

  54. Lian H, Zhuang J, Yang R, Qu F, Wang W, Lin T, et al. Focal cryoablation for unilateral low-intermediate-risk prostate cancer: 63-month mean follow-up results of 41 patients. Int Urol Nephrol. 2016;48(1):85–90.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Teikyo University School of Medicine, Tokyo, Japan

    Masaki Kimura & Satoru Muto

  2. Department of Urology, Duke University, Durham, NC, USA

    Kae Jack Tay

  3. Department of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan

    Shigeo Horie

Authors
  1. Masaki Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kae Jack Tay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoru Muto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shigeo Horie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kae Jack Tay .

Editor information

Editors and Affiliations

  1. Department of Surgery, Duke Cancer Institute, Durham, North Carolina, USA

    Thomas J. Polascik

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Kimura, M., Tay, K.J., Muto, S., Horie, S. (2017). Focal Therapy and Active Surveillance of Prostate Cancer in East and Southeast Asia. In: Polascik, T. (eds) Imaging and Focal Therapy of Early Prostate Cancer. Current Clinical Urology. Springer, Cham. https://doi.org/10.1007/978-3-319-49911-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-49911-6_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-49910-9

  • Online ISBN: 978-3-319-49911-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation